{
    "clinical_study": {
        "@rank": "153053", 
        "acronym": "TRANSCEND", 
        "arm_group": [
            {
                "arm_group_label": "EXPAREL", 
                "arm_group_type": "Active Comparator", 
                "description": "EXPAREL (266mg/20 ml) with 40 mL of 0.9% normal saline for a total volume of 60 mL, 30 mL to be administered to the right TAP and 30 mL to be administered to the left TAP"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Sham Comparator", 
                "description": "The placebo control will be established using a grade-2 sham, no infiltration will occur"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this prospective, blinded assessor, randomized trial is to assess opioid use\n      and patient-reported outcomes of EXPAREL as a foundation in postsurgical pain therapy in\n      Transversus Abdominis Plane (TAP) infiltration in lower abdominal surgical procedures."
        }, 
        "brief_title": "EXPAREL Administered by Infiltration Into the TAP for Prolonged Postsurgical Analgesia in Lower Abdominal Surgeries", 
        "completion_date": {
            "#text": "February 2014", 
            "@type": "Actual"
        }, 
        "condition": "Postsurgical Analgesia", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Males and females >18 years of age\n\n          -  American Society of Anesthesiologists (ASA) physical status 1-3\n\n          -  Undergoing either lower abdominal surgery defined as Laparoscopic Hysterectomy\n             (female), Laparoscopic Myomectomy (female), Laparoscopic Colectomy (male/female)\n\n          -  Physically and mentally able to give full informed consent to participate in this\n             study and complete all study assessments within the timeframes required (including\n             electronic diaries should patient be discharged prior to day 4)\n\n          -  Capable of returning the diary after POD 4 by mail (preferably) or upon follow up\n             visit.\n\n        Exclusion Criteria:\n\n          -  History of hypersensitivity or idiosyncratic reactions to amide-type local\n             anesthetics.\n\n          -  Any patient whose anatomy, or surgical procedure, in the opinion of the Investigator,\n             might preclude the potential successful local administration of EXPAREL.\n\n          -  Patients who have received any investigational drug within 30 days prior to EXPAREL\n             administration, or planned administration of another investigational product or\n             procedure during their participation in this study.\n\n          -  Any chronic condition requiring use of opioids for treatment of a medical condition\n             for 2 weeks or more prior to surgery.\n\n          -  Confirmed pregnancy at time of enrollment or breast feeding (females of child-bearing\n             potential).\n\n          -  Patients that would constitute a contraindication to participation in the study, or\n             cause inability to comply with the study requirements.\n\n          -  Any patient with diagnosed or potential metastatic disease.\n\n          -  Any condition that in the investigator's opinion might be harmed or be a poor\n             candidate for participation in the study (such as patients requiring long acting\n             opioids as part of the induction medications).\n\n          -  Initiation of treatment with any of the following medications within 1 month of study\n             drug administration or if the medication(s) are being given to control pain:\n             selective serotonin reuptake inhibitors (SSRIs), selective norepinephrine reuptake\n             inhibitors (SNRIs), gabapentin, pregabalin (Lyrica\u00ae), or duloxetine (Cymbalta\u00ae)\n\n          -  History of suspected or known addiction to, or abuse of, illicit drug(s),\n             prescription medicine(s), or alcohol within the past 2 years."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "74", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "August 6, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01919190", 
            "org_study_id": "MSE402"
        }, 
        "intervention": [
            {
                "arm_group_label": "EXPAREL", 
                "intervention_name": "EXPAREL", 
                "intervention_type": "Drug", 
                "other_name": "bupivacaine liposome injectable suspension."
            }, 
            {
                "arm_group_label": "Placebo", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug", 
                "other_name": "Placebo using grade-2 sham, no infiltration"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "February 21, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Winter Park", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "32792"
                    }, 
                    "name": "Florida Hospital"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Savannah", 
                        "country": "United States", 
                        "state": "Georgia", 
                        "zip": "31404"
                    }, 
                    "name": "Memorial Health University Medical Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Chicago", 
                        "country": "United States", 
                        "state": "Illinois", 
                        "zip": "60208"
                    }, 
                    "name": "Northwestern University"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Louisville", 
                        "country": "United States", 
                        "state": "Kentucky", 
                        "zip": "40202"
                    }, 
                    "name": "University of Louisville"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Pittsfield", 
                        "country": "United States", 
                        "state": "Massachusetts", 
                        "zip": "01210"
                    }, 
                    "name": "Berkshire Medical Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Minneapolis", 
                        "country": "United States", 
                        "state": "Minnesota", 
                        "zip": "55404"
                    }, 
                    "name": "University of Minnesota"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Bronx", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "10467"
                    }, 
                    "name": "Montefiore Medical Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Durham", 
                        "country": "United States", 
                        "state": "North Carolina", 
                        "zip": "27705"
                    }, 
                    "name": "Duke University"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Cleveland", 
                        "country": "United States", 
                        "state": "Ohio", 
                        "zip": "44111"
                    }, 
                    "name": "Fairview Hospital"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Columbus", 
                        "country": "United States", 
                        "state": "Ohio", 
                        "zip": "43210"
                    }, 
                    "name": "The Ohio State University"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Philadelphia", 
                        "country": "United States", 
                        "state": "Pennsylvania", 
                        "zip": "19107"
                    }, 
                    "name": "Thomas Jefferson University"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Pittsburgh", 
                        "country": "United States", 
                        "state": "Pennsylvania", 
                        "zip": "15215"
                    }, 
                    "name": "UPMC St. Margaret's Hospital"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Houston", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "77081"
                    }, 
                    "name": "St. John Hospital"
                }
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "Assessing the Impact of EXPAREL(R) on Opioid Use and Patient Reported Outcomes When Administered by Infiltration Into the Transversus Abdominis Plane (TAP) Under Ultrasound Guidance for Prolonged Postsurgical Analgesia in Lower Abdominal Surgeries", 
        "overall_official": {
            "affiliation": "Pacira Pharmaceuticals, Inc", 
            "last_name": "Kay Warnott, RN", 
            "role": "Study Director"
        }, 
        "overall_status": "Terminated", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "December 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "description": "Measure of total opioid consumption from surgery through 4 days postsurgery - primary endpoint is mean difference in total opioid consumption until discharge readiness criteria are fulfilled or 4 days postsurgery.", 
                "measure": "Total opioid consumption from end of surgery through 4 days postsurgery", 
                "safety_issue": "No", 
                "time_frame": "From surgery through 4 days postsurgery"
            }, 
            {
                "description": "Severity of postsurgical pain, satisfaction with pain management, and impact of opioid-related symptom distress measured using the Overall Benefit of Analgesic Score (OBAS) - primary endpoint is mean difference in OBAS at discharge readiness criteria fulfillment or 4 days postsurgery.", 
                "measure": "Overall benefit of analgesic score (OBAS)", 
                "safety_issue": "No", 
                "time_frame": "Assessed daily through Day 4 postsurgery"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01919190"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Extent and degree of anesthetic blockage measured using a 5-point sensation scale.", 
                "measure": "Extent and degree of anesthetic blockade", 
                "safety_issue": "No", 
                "time_frame": "Prior to TAP, immediately postoperatively, and daily through discharge or Day 4"
            }, 
            {
                "description": "Severity of postsurgical pain measured using an 11-point numerical rating scale (NRS 0-10).", 
                "measure": "Severity of postsurgical pain", 
                "safety_issue": "No", 
                "time_frame": "Immediately in PACU postsurgery and prior to pain medication until discharge (or Day 4)"
            }, 
            {
                "description": "Measured using the Quality of Recovery 15 questionnaire (QoR-15)", 
                "measure": "Quality of recovery", 
                "safety_issue": "No", 
                "time_frame": "Daily through Post Op Day 4"
            }, 
            {
                "description": "Frequency of patient calls post-discharge related to pain and unscheduled hospital/surgeon visits", 
                "measure": "Frequency of patient calls post-discharge related to pain and unscheduled hospital/surgeon visits", 
                "safety_issue": "No", 
                "time_frame": "Post-discharge through 4 days postsurgery"
            }
        ], 
        "source": "Pacira Pharmaceuticals, Inc", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Pacira Pharmaceuticals, Inc", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "August 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2014", 
        "why_stopped": "Due to reasons unrelated to safety.  However, a primary efficacy endpoint signal was seen\n    during a pre-specified interim analysis."
    }
}